Skip to main content

Rare Diseases

Kikuchi’s Dz (AKA Kikuchi-Fujimoto dz) is rare, affects young women >men w/ recurrent necrotizing lymphadenitis (may assoc w/ SLE, MAS, TB); Sx included fever, flu-Sxs, Wt loss, night sweats, Hi CRP/LFTs, lymphopenia, uncommon arthritis, organomegaly

Dr. John Cush @RheumNow( View Tweet )

Oct 18, 2021

RheumNow Podcast – Quackademia (10.15.2021)

Oct 14, 2021

Dr. Jack Cush reviews the FDA approvals, news and the latest journal articles from the past week on

Read Article
Decline in the incidence of Behcets Dz? Between 2004 to 2017 Korea has seen BD decreased from 8.15/100K (2004) to 1.51/100K (2017), an 81.5% decrease, greater for women and middle-aged people, but no change survival or mortality

Dr. John Cush @RheumNow( View Tweet )

Oct 14, 2021

Still’s Disease Following COVID-19 Vaccination

Oct 14, 2021

Both systemic onset juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease are acquired autoinflammatory disorders of uncertain etiology. Yet recent reports of AOSD onset and flare following COVID-19 vaccinations may have important mechanistic implications.

Read Article

Clinical Associations with Myositis Antibodies

Oct 07, 2021

While myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs) may have prognostic value through their clinical associations, many patients will not have them and overall, they are poorly predictive of a malignancy risk. 

Read Article

Lupus Frailty Index Predicts Organ Damage

MedPage Today
Oct 05, 2021

Patients with longstanding systemic lupus erythematosus (SLE) who were considered frail were more likely to accrue disease damage over time, a secondary analysis of data from a Chicago lupus cohort found.

On a multivariate analysis that controlled for age, race, and duration of

Read Article

Early Antibiotic Use Increases JIA Risk

Sep 28, 2021

A population based Swedish study of birth records shows that antibiotic exposure in first three years of life to be associated with a future risk of juvenile idiopathic arthritis (JIA), although infections during fetal life or childhood did not increase risk of JIA.

Read Article

Post-Arthroscopic Increase in Septic Arthritis

Sep 27, 2021

A longitudinal study from Iceland shows an increasing number of native joint infections (NJI), with iatrogenic, postarthroscopic infections being of particular concern.

Between 2003-2017 they identified 299 NJI (40 children and 259 adults) with more infections in men (33% women vs 67

Read Article

RheumNow Podcast – I Wanna New Drug.V2 (9.24.2021)

Sep 23, 2021

Almost three years ago to the day, I did a podcast entitled, "I wanna new drug." As I go over this week's podcast, I want to say it again. I want a new drug safe enough to use during pregnancy, for PMR, for GVHD, and more. I'm going to cover these, and other topics including lupus, COVID

Read Article

11 Drugs That Cause Arthritis

Sep 23, 2021

This is the #1 question I get from new consults: “How did I get arthritis?”

But as the aching are asking, they are really thinking these joint complaints must be due to something.

Read Article

High Comorbidity Rates with Inclusion Body Myositis

Sep 21, 2021

Inclusion body myositis (IBM) patients tend to be older than those with idiopathic inflammatory myositis (IIM), but the scope of disease beyond their myositis is not appreciated. Now, a population-based, case-control study suggests both a lower overall survival and high comorbidity burden in

Read Article

Worrisome Maternal Mortality with COVID-19 Infection

Sep 20, 2021

Maternal and fetal outcomes during the COVID-19 pandemic have not been well studied; yet a new retrospective study from Mexico indicates that during the pandemic maternal mortality increased by nearly 57%, with COVID-19 as the cause in 23% of cases.

This surveillance study examined

Read Article

Canakinumab Use in Periodic Febrile Disorders

Sep 16, 2021

A retrospective records review of patients with periodic fever syndromes (PFS)  receiving IL-1 inhibitor treatment with canakinumab (CAN), shows CAN to be effective and safe in a variety of PFS patients.

Read Article

Effect of Diet on COVID Outcomes

Sep 15, 2021

A smartphone-based symptom study of COVID-19 patients has shown that a healthy plant-based diet was associated with lower risk and severity of COVID-19, especially amongst those living in areas with higher socioeconomic deprivation.

Data was collected from 592,571 individuals

Read Article

Risk Factors Associated with Systemic Sclerosis Hospitalization

Sep 09, 2021

A retrospective study of systemic sclerosis patients shows that acute hospitalization and mortality were not uncommon and were often linked to SSc-related lung disease.

Record review of 95 SSc patients from a single-centre cohort seen between 2010 and 2020 found that over half (53

Read Article

Lymphoma in RA: Disease Activity Matters

MedPage Today
Sep 08, 2021

Among patients with rheumatoid arthritis (RA), the strongest risk factors for the development of lymphoma were disease activity and severity, French researchers found.

In a multivariate analysis, having a high Disease Activity Score in 28 joints (DAS28) at baseline conferred twice the risk for

Read Article

COVID Breakthrough Infections in Rheumatic Patients

Sep 08, 2021

Analysis of records from the Mass General Brigham healthcare system in the Boston area, shows that breakthrough infections (after receiving SARS-CoV-2 vaccines) in patients with systemic autoimmune rheumatic diseases (SARDs) are not uncommon, and may be severe or fatal.


Read Article

Not All Immunosuppression Alters Vaccine Immunogenicity

Sep 02, 2021

Chronic inflammatory disease (CID) patients are urged to receive the COVID-19 vaccines; but when a cohort of CID patients treated with immunosuppressive medications were given an mRNA-based SARS-CoV-2 vaccination, only those treated with glucocorticoids and B cell depleting therapies (BCDT)

Read Article

TNF Inhibitor Induced IgA Vasculitis in IBD

Aug 31, 2021

A new descriptive series shows an uncommon association between IgA vasculitis (IgAV) and inflammatory bowel diseases (IBD), with most cases interestingly arising after  or during anti-TNF-α therapy.

A retrospectively analysis of the GETAID and FVSG networks identified, 43 patients

Read Article

RheumNow Podcast – COVID Marching Amidst the Madness (8.27.2021)

Aug 26, 2021

We have a lot of news, information and approvals to review and discuss, though I need to begin with what's weighing heavily on my mind. After, we'll dive into what we learned this week.

Read Article

Rheumatic Events With Checkpoint Inhibitors: Tumor Type Matters

MedPage Today
Aug 24, 2021

Among the factors that were associated with an increased risk for the development of rheumatic immune-related adverse events following cancer treatment with immune checkpoint inhibitors (ICIs) was the type of malignancy involved, a large case-control study found.

Read Article

FDA Approves First COVID-19 Vaccine

Aug 23, 2021

Today, the U.S. Food and Drug Administration (FDA) approved the first COVID-19 vaccine, manufactured by Pfizer-BioNTech COVID-19 the vaccine, now marketed as Comirnaty (koe-mir’-na-tee), is approved for the prevention of COVID-19 disease in individuals 16 years of age and older.


Read Article

Tocilizumab in Refractory Skin and Joint Scleroderma

Aug 18, 2021

The interleukin-6 inhibitor, tocilizumab (TCZ), was studied in a cohort of difficult systemic sclerosis (SSc)  and was shown to be effective in refractory joint and skin disease with good long-term retention rates and disease stabilization.

TCZ is currently FDA approved for use in SSc

Read Article

Booster Shots for Rheumatology Patients on Immunosuppressive Medications

ACR Press Release
Aug 16, 2021

ATLANTA – The CDC's Advisory Committee on Immunization Practices today recommended that rheumatology patients being actively treated with high-dose corticosteroids, alkylating agents, antimetabolites, TNF blockers, and other biologic agents that are immunosuppressive or immunomodulatory receive

Read Article

RheumNow Podcast – Booster Shots for COVID (8.13.2021)

Aug 13, 2021

Dr. Jack Cush reviews the news and journal reports from the past week on

  1. In a head to head trial Upadacitinib was superior to Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis. 24wk DBRCT, 924 pts given either UPA 30/d vsDUP 300 EOW. ESI75 response@

Read Article